WSJ : Sony Re-Evaluates Support for Free Music Streaming

Sony Re-Evaluates Support for Free Music Streaming
Move Prompted By Taylor Swift Pulling Music from Spotify

TOKYO—A top Sony Corp. executive said Tuesday that the company is re-evaluating its support for free, advertiser-supported online music after U.S. pop star Taylor Swift pulled her music from Spotify, the popular digital streaming service.

“Actually, a lot of conversation has taken place over the last week in the light of that,” said Kevin Kelleher, chief financial officer of Sony Music. “What it all really comes down to is how much value are the music company and the artist getting from the different consumption methods.”

Ms. Swift’s decision this month to leave Spotify, which shares with artists a portion of the proceeds from ad sales and from fees for its paid, ad-free premium version, sent shock waves through the music business. With sales of CDs in a long-term slump and digital downloads beginning to decline, the industry has been looking to streaming as its brightest hope.

Despite Ms. Swift’s thumbs-down to Spotify, Mr. Kelleher said Sony remained “very encouraged” by the growth of subscription-based streaming services, which let users skip ads in exchange for monthly fees.

The company said Tuesday, at a briefing for analysts and investors, that it expects music-division revenue to increase to a range of $4.8 billion to $5.2 billion for the fiscal year ending in March 2018, from $4.8 billion in the current year.

“The key question is, are the free, ad-supported services taking away from how quickly and to what extent we can grow those paid services?” Mr. Kelleher said. “That’s something we’re paying attention to as content owners who license our content to the different platforms. It’s an area that’s gotten everyone’s attention.”

That sentiment has been growing in the industry. One record-label executive told The Wall Street Journal recently that he regretted ever having agreed to allow licensees to offer any on-demand listening features free. “In hindsight we made a mistake,” he said.

Mr. Kelleher’s comments came at the first of two briefings that Sony has scheduled to provide updates on the progress of its restructuring. Tuesday’s session focused on the entertainment arm, including music and the Hollywood studio division, while a meeting next week is devoted to the electronics business.

Sony Chief Financial Officer Kenichiro Yoshida, smartphone chief Hiroki Totoki and PlayStation videogame head Andrew House are all expected to take the stage on the second day.

While its electronics operation remains challenged, with smartphone sales falling short of expectations, Sony has moved to cut losses in businesses such as making television sets. Fixing the Xperia phone business is an urgent task for Sony, Chief Executive Kazuo Hirai said. Mr. Totoki is expected to provide details about how he will rebuild the Xperia arm—efforts that are likely to extend into the next fiscal year.

Sony’s entertainment arm, meanwhile, continues to deliver steady earnings.

“Some say the entertainment unit is just a side business to Sony, but it is an important pillar for us as it brings a steady flow of profits,” Mr. Hirai said.

Sony said it expects its Hollywood studio business, Sony Pictures Entertainment, to generate revenue of $10 billion to $11 billion in fiscal year 2018, up from $8.1 billion in the current year. Sony executives said the company plans to invest in markets such as India, where the company has a growing slate of TV channels, as it contends with slowing growth elsewhere.

Sony executives said that the activist investor Daniel Loeb recently dropped a campaign to get Sony to partially spin off its entertainment arm, hoping to unlock what he described as hidden value in that side of the company. Mr. Loeb said in October that his hedge fund, Third Point LLC, had sold its Sony stake, acquired in May 2013, making a 20% gain.

After Mr. Loeb became involved, Sony moved to increase transparency around the entertainment arm’s operations in an effort to position it as central to the company’s turnaround efforts.

>>> SunEdison: Color on Wind Acquisition -->+4.2% Pre-market

SunEdison: Color on Wind Acquisition

  • Brean Capital (From 11/18) note SUNE and its yieldco, Terraform Power (TERP) announced a definitive agreement to acquire First Wind for $2.4B. As a result, SUNE raised its 2015 project installation and CAFD from TERP guidance and indicated its timetable for receiving Incentive Distribution Rights (IDR's) from TerraForm Power has been accelerated. Firm views the acquisition as transformative and should improve the Company's overall risk profile relative to its peers. Maintain Buy rating and $23 target.
  • FBR Capital (From 11/18) notes transaction marks the entry of SunEdison into the wind sector, and should transform the company from being a pure solar developer to a more diversified operator of renewable energy assets. Based on firm's existing portfolio estimates for 2017, and assuming SunEdison successfully adds about 2.1GW of wind assets and drops them into TerraForm, the pro forma asset mix would be about 60% solar and 40% wind. At the first glance, FBR estimates that the operating assets were acquired at a discount to some other recent transactions, while the cash value paid for the pipeline should generate a low double digit ROI, assuming only 2.1GW of assets are successfully developed by 2017.
  • Needham Research notes it likes the deal as it: 1) substantially increases SUNE's TAM with a proven team; 2) accelerates growth with faster project construction; 3) enables SUNE (and TERP) to become the largest renewable energy developer; and 4) increases value creation for SUNE through TERP. Needham sees the increased leverage on its balance sheet as an incremental risk, but mgmt should be able to navigate any issue given its proven track record in financing. Reiterate Buy and raise tgt to $28.

(BN) Sanofi Said to Consider Smith & Nephew, Takeda Executives as CEO


Sanofi Said to Consider Smith & Nephew, Takeda Executives as CEO
2014-11-19 13:23:17.789 GMT


By Albertina Torsoli
Nov. 19 (Bloomberg) -- Sanofi has considered Olivier Bohuon
of medical-device maker Smith & Nephew Plc and Takeda
Pharmaceutical Co.’s Christophe Weber as possible replacements
for ousted Chief Executive Officer Chris Viehbacher, said people
familiar with the situation.
The board of Paris-based Sanofi has started contacting
potential candidates and wants to move quickly with the
recruiting, said the people, who asked not to be identified
discussing private matters. Eric Cornut, Novartis AG’s chief
ethics officer, also is a potential candidate, as is Olivier
Brandicourt, head of Bayer AG’s health-care business, some of
the people said.
The names cited in the search indicate Sanofi is focusing
mostly on French executives with pharmaceutical experience. The
company last month ousted Viehbacher, a Canadian-German, saying
relations between him and the board weren’t close enough and
that he failed to sufficiently execute the strategy. Some
investors said there was a culture clash between Viehbacher and
the board, which is mostly French. Chairman Serge Weinberg said
nationality wouldn’t be a criteria in the search.
“You’ve got to have somebody who is agile enough to deal
with resource allocation on the one hand, but also has the
ability to catch on to changes,” Michael Leuchten, an analyst
at Barclays Plc in London, said by phone. “This is where people
are a little bit concerned now, because people thought
Viehbacher had that.”

Bohuon, Weber

Bohuon previously worked at drugmakers Pierre Fabre SA,
Abbott Laboratories and GlaxoSmithKline Plc. He declined to
comment on the Sanofi job when asked about it on a conference
call last month.
Weber, another former Glaxo executive, joined Osaka, Japan-
based Takeda as chief operating officer in April and the company
plans to have him become CEO next year. He’s unlikely to accept
a Sanofi offer after such a short time at Takeda, three people
said.
Bohuon, Weber and Brandicourt are French. Cornut, who is
Swiss, ran Novartis’s French operations. The board may be
considering other candidates and could still turn to someone
else, one person said.
AstraZeneca Plc CEO Pascal Soriot also remains a possible
candidate, although he has already been approached and said he
wasn’t interested, the people said. Soriot, who is French, is
unlikely to leave his current job for the Sanofi one, they said.
Asked about the job on a Nov. 6 conference call, Soriot said he
couldn’t say whether he was interested.

Cambridge Meeting

The search is under way as Weinberg, who’s serving as
interim CEO, prepares to brief investors tomorrow in Cambridge,
Massachusetts, on Sanofi’s new medicines, including the insulin
Toujeo and the cholesterol treatment alirocumab.
Weinberg has been busy meeting with employees and others
since becoming interim CEO, two people familiar with his role
said. Within an hour of Viehbacher’s ouster he started calling
members of the executive team to reassure them of the company’s
strategy, one of them said.
The week of Nov. 3 he visited company offices in Cambridge
and New Jersey to meet employees, three people said. He also
spoke by phone and then met in person with Len Schleifer, the
CEO of Regeneron Pharmaceuticals Inc., Sanofi’s partner on
alirocumab and other treatments, according to one person.
Ben Atwell, a spokesman for London-based Smith & Nephew,
Jocelyn Gerst, a Takeda spokeswoman in Deerfield, Illinois, Eric
Althoff at Basel, Switzerland-based Novartis, Jack Cox at Sanofi
and Christian Hartel, a spokesman for Leverkusen, Germany-based
Bayer, declined to comment.

For Related News and Information:
How Sanofi Boss Saw Story End in 60 Hours After Boardroom Tussle
AstraZeneca’s Soriot Tries to Deflect Sanofi CEO Job Speculation
Sanofi CEO’s Ouster Mirrors Teva Corporate Culture Clash: Health
Top health news: HTOP <GO>

--With assistance from Makiko Kitamura in London, Simeon Bennett
in Geneva and Jacqueline Simmons in Paris.

To contact the reporter on this story:
Albertina Torsoli in Geneva at +41-22-317-9202 or
atorsoli@bloomberg.net
To contact the editors responsible for this story:
Phil Serafino at +33-1-5530-6277 or
pserafino@bloomberg.net
Andrew Pollack

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
: EJ -9.4%, LEJU -8.9%, VIPS -5.3%, XUE -4.9%, BBSI -3.5%, KE -1.8%, SNSS -1%


Select metals/mining stocks trading lower: RIO -1.8%, HMY -1.7%, IAG -1.7%, AU -1.6%, BHP -1.5%, VALE -0.5%

Other news: CLF -10.9% (to pursue exit options for its Eastern Canadian operations), CLVS -7% (reported Interim data from rociletinib (CO-1686) Phase 1/2 study), RSH -3.5% (seeing reports that Monach has ended negotiations to take over a $140 mln loan), KKR -2.5% (may be considering PETM bid, according to reports), HMC -2.1% (related to Takata air bag recall), SDRL -2% (still checking), TTM -1.3% (related to Takata air bag recall), TRP -1.1% (Keystone Pipeline bill did not get 60 votes needed in Senate), FOLD -0.8% (prices 13,850,000 shares of its common stock at $6.50 per share)

Analyst comments: BBRY -5.7% (downgraded to Underweight from Equal-Weight at Morgan Stanley), TSLA -3% (Hearing Morgan Stanley cutting FY15 EPS below consensus), MOV -1.4% (downgraded to Mkt Perform from Outperform at Barrington Research), DNR -0.5% (downgraded to Hold at Wunderlich)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
: LITB +8.9%, SGYP +7.4%, DL +5.2%, LZB +4.3%, LOW +3.9%, PETM +3.6%, JACK +3.5%, MNK +3.5%, SPLS +2.7%, TGT +2.6%, MTSI +1.4%

Select Brazil related names showing strength: ABGB +5.9%, EBR +4.4%, ABEV +3.1%, GOL +3.1%, CPL +2.5%, BBD +2%, VIV +1.7%, GGB +1.5%, TSU +1.5%, .

Other news: AGIO +9.8% (announced early Phase 1 data showing clinical acivity of AG-120 as a single agent in advanced acute myeloid leukemia), OMER +6.5% (announced positive data using OMS721), NBG +4.9% (cont move higher following strong Greece mkts overnight), PERY +4.3% (CalSTRS, Legion Partners call on PERY board to form an independent committee to evaluate strategic alternatives), SUNE +3.7% (cont strength pre-mkt after yday's 29% move), ENPH +2.8% (Co and SolarWorld enter global strategic partnership), CEL +2.5% (still checking, but announced that a purported class action was filed against the co and another cellular operator ), VA +2.5% (cont momentum post IPO), AMRN +2.3% (light volume), PLKI +1.6% (Red Mountain Capital disclosed a 5.1% stake in a 13-D Filing; Continue to engage in dialogue with mgmt), LNBB +1.4% (seeing reports that co is working with Sandler O'Neil to explore a sale), CRAY +1.1% (announced that Cloudera Enterprise is now pre-integrated into Cray's new big data analytics appliance)

Analyst comments: JAH +4.4% (initiated with a Buy at BTIG Research), ASML +2.3% (upgraded to Buy from Hold at Evercore ISI), POT +1.8% (upgraded to Outperform from Mkt Perform at Raymond James), MOS +1.6% (upgraded to Positive from Neutral at Susquehanna)

>>> OPLK - To be Acquired by Koch Industries for $24.25/shr in transaction value

To be Acquired by Koch Industries for $24.25/shr in transaction valued at $445M in cash 

Under the terms of the agreement, which has been approved by each company's Board of Directors, Koch Optics will commence a tender offer and subsequent merger for all of the outstanding shares of Oplink common stock for $24.25 per share.

The purchase price represents a 26% premium to the average closing price for the 30 days prior to the announcement and a 14% premium to the closing price on November 18, 2014.